Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr21.70 SEK
Change Today -0.10 / -0.46%
Volume 13.1K
NVP On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
OTC US
As of 11:29 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

neurovive pharmaceutical (NVP) Snapshot

Open
kr22.00
Previous Close
kr21.80
Day High
kr22.00
Day Low
kr21.60
52 Week High
08/5/14 - kr82.00
52 Week Low
06/1/15 - kr16.60
Market Cap
667.0M
Average Volume 10 Days
43.3K
EPS TTM
kr-1.90
Shares Outstanding
30.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROVIVE PHARMACEUTICAL (NVP)

Related News

No related news articles were found.

neurovive pharmaceutical (NVP) Related Businessweek News

No Related Businessweek News Found

neurovive pharmaceutical (NVP) Details

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. Its product portfolio includes CicloMulsion, a drug candidate, which is in Phase III clinical study for cell protection against reperfusion injury during heart attack treatment; NeuroSTAT, a drug candidate that is in Phase IIa clinical study for the treatment of traumatic brain injuries; and NVP019, an intravenous formulation that is in pre-clinical phase for treating myocardial infarct and traumatic brain injury. The company is also developing NVP014 for brain cell protection in stroke; NVP015 for treating mitochondrial diseases in children and drug-induced mitochondrial dysfunction; and NVP018, an antiviral pharmaceutical product to treat hepatitis B and C. It has collaboration agreements with Isomerase Therapeutics and Sihuan Pharmaceutical; and development and commercialization outlicensing agreement with OnCore BioPharma, as well as agreements with Fresenius Kabi and Lyon University Hospital. The company was founded in 2000 and is headquartered in Lund, Sweden.

13 Employees
Last Reported Date: 05/20/15
Founded in 2000

neurovive pharmaceutical (NVP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr2.0M
Compensation as of Fiscal Year 2014.

neurovive pharmaceutical (NVP) Key Developments

NeuroVive Pharmaceutical AB, Special/Extraordinary Shareholders Meeting, Jun 11, 2015

NeuroVive Pharmaceutical AB, Special/Extraordinary Shareholders Meeting, Jun 11, 2015.

NeuroVive Pharmaceutical AB Reports Results of Phase III CIRCUS Study in Acute Myocardial Infarction

NeuroVive Pharmaceutical AB reported that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment elevation acute myocardial infarction (STEMI) did not meet its primary clinical endpoint in a topline analysis. It is anticipated that the full results of the 12-month data from the CIRCUS study will be made available in the third quarter of 2015. The primary endpoint is a composite of three separate outcomes: mortality, hospitalization for heart failure and left-ventricular (LV) remodeling at 12 months post acute myocardial infarction. The primary objective of the study was to determine whether CicloMulsion® can improve STEMI patient clinical outcomes 12 months after administration. CicloMulsion® or placebo was administered directly prior to percutaneous coronary intervention (PCI), a common procedure to reopen the coronary artery allowing the return of blood flow to the heart. The study will continue for a further two years to investigate longer term outcomes. CicloMulsion® is an investigational product and has not been approved by regulatory agencies for the treatment of any medical condition. The impact of the CIRCUS results on the future development of CicloMulsion® will be communicated in the second half of 2015.

NeuroVive Pharmaceutical AB Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion® in South Korea

NeuroVive Pharmaceutical AB announceD that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi’s local affiliate for the development and commercialization of CicloMulsion® in South Korea. Under the agreement NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. CicloMulsion® is being developed for the treatment of reperfusion injury in cardiovascular disease. CicloMulsion® is in a clinical development phase, which means that the probability of reaching the market is dependent on a number of factors outside of NeuroVive’s control. These include research-related and clinical risks such as the product failing to demonstrate satisfactory efficacy or safety during development, and regulatory risk in the form of regulatory authorities withholding market approval or pricing reimbursement or requiring an extension of or delay in the time required before the product can reach the market. There are numerous other circumstances attributable to the general development process, as for all products of a similar kind in clinical development. Investors are urged to evaluate the publically available documents NeuroVive has published for further general information regarding the development of NeuroVive’s products. Current status of NeuroVive’s projects and drug candidates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVP:SS kr21.70 SEK -0.10

NVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVP.
View Industry Companies
 

Industry Analysis

NVP

Industry Average

Valuation NVP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 74.9x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 67.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROVIVE PHARMACEUTICAL, please visit www.neurovive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.